deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT02047149

Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia

Phase I Study to Evaluate the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Patients With Chronic Myelogenous Leukemia

Sponsor: Bristol-Myers Squibb

Conditions Chronic Myelogenous Leukemia
Interventions Daily dosing of Zileuton/Dasatinib Daily dosing with Zileuton/Dasatinib for CML Dosing with Zileuton/Dasatinib in CML Zileuton (Zyflo®) Dasatinib (Sprycel®)
Updated 6 times since 2017 Last updated: Sep 29, 2016 Started: Jan 31, 2014 Primary completion: Jun 30, 2016 Completion: Jun 30, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low accrual

Other terminated trials from Bristol-Myers Squibb

See all terminations from Bristol-Myers Squibb

Other Chronic Myelogenous Leukemia trials with similar outcome

Browse all Chronic Myelogenous Leukemia trials

This PHASE1 trial investigates Chronic Myelogenous Leukemia and is currently terminated or withdrawn. Bristol-Myers Squibb leads this study, which shows 6 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1

    First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • University of Massachusetts, Worcester
Data source: University of Massachusetts, Worcester

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations